BR112017014433A2 - proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica - Google Patents

proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica

Info

Publication number
BR112017014433A2
BR112017014433A2 BR112017014433-6A BR112017014433A BR112017014433A2 BR 112017014433 A2 BR112017014433 A2 BR 112017014433A2 BR 112017014433 A BR112017014433 A BR 112017014433A BR 112017014433 A2 BR112017014433 A2 BR 112017014433A2
Authority
BR
Brazil
Prior art keywords
protein
modified
dna
proteinase
modified dnase
Prior art date
Application number
BR112017014433-6A
Other languages
English (en)
Inventor
Chen Zeltsburg Lilach
Ruderfer Ilya
Shulman Avidor
Fux Liat
Ugortsev Yulia
Neta Hagit
Gelley Sivan
Lavee Laviad Elad
Shaaltiel Yoseph
Original Assignee
Protalix Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protalix Ltd. filed Critical Protalix Ltd.
Publication of BR112017014433A2 publication Critical patent/BR112017014433A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica, fornece uma proteína dnase i modificada na qual um ou mais aminoácido(s) de uma proteína dnase i é(são) não celularmente modificado(s); a proteína dnase i modificada exibe uma atividade hidrolítica de dna na presença de actina e uma atividade hidrolítica de dna melhorada comparada a uma proteína dnase i não modificada homóloga. processos de preparação da proteína dnase i modificada e usos respectivos, por exemplo, na redução de um teor de dna no escarro e/ou no tratamento de uma doença ou condição associada ao excesso de dna extracelular em um fluido, secreção ou tecido de um indivíduo também são fornecidos.
BR112017014433-6A 2015-01-04 2016-01-04 proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica BR112017014433A2 (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562099565P 2015-01-04 2015-01-04
US201562099560P 2015-01-04 2015-01-04
US62/099,560 2015-01-04
US62/099,565 2015-01-04
US201562163497P 2015-05-19 2015-05-19
US62/163,497 2015-05-19
US201562169724P 2015-06-02 2015-06-02
US62/169,724 2015-06-02
US201562247856P 2015-10-29 2015-10-29
US62/247,856 2015-10-29
PCT/IL2016/050003 WO2016108244A1 (en) 2015-01-04 2016-01-04 Modified dnase and uses thereof

Publications (1)

Publication Number Publication Date
BR112017014433A2 true BR112017014433A2 (pt) 2018-05-15

Family

ID=55442842

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014433-6A BR112017014433A2 (pt) 2015-01-04 2016-01-04 proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica

Country Status (13)

Country Link
US (2) US11225648B2 (pt)
EP (1) EP3240896A1 (pt)
CN (1) CN107406837A (pt)
AU (1) AU2016204793B2 (pt)
BR (1) BR112017014433A2 (pt)
CA (1) CA2970216A1 (pt)
HK (1) HK1245822A1 (pt)
IL (1) IL253208B2 (pt)
MX (1) MX2017008567A (pt)
NZ (1) NZ733912A (pt)
RU (1) RU2017125957A (pt)
WO (1) WO2016108244A1 (pt)
ZA (1) ZA201704903B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406837A (zh) * 2015-01-04 2017-11-28 波塔力克斯有限公司 修饰的dna酶及其用途
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
BR112019009925A2 (pt) 2016-11-17 2019-10-08 Iovance Biotherapeutics Inc método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer .
KR20200122320A (ko) * 2018-01-16 2020-10-27 씨엘에스 테라퓨틱스 리미티드 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료
WO2020014226A1 (en) * 2018-07-09 2020-01-16 Gro Biosciences Inc. Non-standard amino acid containing compositions and uses thereof
WO2020106709A1 (en) * 2018-11-19 2020-05-28 Gro Biosciences Inc. Human dnase for lung disease
EP4225903A1 (en) 2020-10-07 2023-08-16 Protalix Ltd. Long-acting dnase
AU2022224584A1 (en) 2021-02-19 2023-09-21 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
EP0449968B1 (en) * 1988-12-23 1999-02-24 Genentech, Inc. Process for the preparation of human dnase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5394866A (en) 1991-03-05 1995-03-07 Aradigm Corporation Automatic aerosol medication delivery system and methods
DE69329110T2 (de) 1992-04-09 2001-03-22 Omron Tateisi Electronics Co Ultraschallzerstäuber
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5507277A (en) 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
US5888477A (en) 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US5694919A (en) 1993-01-29 1997-12-09 Aradigm Corporation Lockout device for controlled release of drug from patient-activated dispenser
CA2184581C (en) * 1994-03-04 2005-02-22 Hak-Kim Chan Improved dnase liquid solutions
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US5509404A (en) 1994-07-11 1996-04-23 Aradigm Corporation Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
GB2316323B (en) 1996-06-20 1999-09-22 Aid Medic Ltd Dispensing system
WO1998029096A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems Aerosolized hydrophobic drug
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
US6397838B1 (en) 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
GB9903433D0 (en) 1999-02-15 1999-04-07 The Technology Partnership Plc Droplet generation method and device
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE10013093B4 (de) 2000-03-17 2005-12-22 Inamed Gmbh Vorrichtung zur kontrollierten Inhalation therapeutischer Aerosole
EP1249244A1 (en) 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
DE10123749A1 (de) 2001-05-16 2002-12-12 Inamed Gmbh Vorrichtung zum Verabreichen von Aerosolen
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20030044493A1 (en) 2001-06-28 2003-03-06 Rettey David C. Container comprising edible manifold
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
WO2006130034A1 (fr) 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
CN101693132B (zh) 2004-04-02 2013-05-22 美国政府健康及人类服务部，疾病控制和预防中心 气雾化输送系统和方法
US20070259367A1 (en) 2006-05-03 2007-11-08 Ax Roy L Method to diagnose and increase fertility of mammalian semen using dnase as a diagnostic marker and therapeutic agent
WO2008039989A2 (en) 2006-09-28 2008-04-03 Transave, Inc. Formulations of dnase and methods of use thereof
RU2009118359A (ru) 2006-10-18 2010-11-20 Перинесс Лтд. (Il) Способ и фармацевтическая композиция для диагностики и лечения недостаточности репродуктивной функции у мужчин
PL2095825T3 (pl) 2006-11-28 2011-12-30 Cls Therapeutics Ltd Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu
WO2011004476A1 (ja) 2009-07-09 2011-01-13 パイオニア株式会社 スピーカ装置
EP2809780B1 (en) * 2012-02-01 2018-05-02 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
CN107406837A (zh) * 2015-01-04 2017-11-28 波塔力克斯有限公司 修饰的dna酶及其用途

Also Published As

Publication number Publication date
ZA201704903B (en) 2023-10-25
MX2017008567A (es) 2018-04-26
US11225648B2 (en) 2022-01-18
US20180112201A1 (en) 2018-04-26
CN107406837A (zh) 2017-11-28
EP3240896A1 (en) 2017-11-08
HK1245822A1 (zh) 2018-08-31
IL253208B2 (en) 2023-03-01
AU2016204793B2 (en) 2021-12-16
IL253208A0 (en) 2017-08-31
NZ733912A (en) 2023-04-28
IL253208B (en) 2022-11-01
AU2016204793A1 (en) 2017-08-10
CA2970216A1 (en) 2016-07-07
WO2016108244A1 (en) 2016-07-07
US11814657B2 (en) 2023-11-14
US20220106578A1 (en) 2022-04-07
RU2017125957A (ru) 2019-02-04

Similar Documents

Publication Publication Date Title
BR112017014433A2 (pt) proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica
BR112018003316A2 (pt) compostos e métodos para entrega transmembrana de moléculas
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
BR112016022553A2 (pt) Compostos e métodos para entrega transmembrana de moléculas?
BR112019001887A2 (pt) composições e métodos para o tratamento de doença associada a cep290
BR112016016705A8 (pt) Processo para a purificação de oligossacarídeos neutros de leite humano (hmo), oligossacarídeo de leite humano (hmo) neutro, e uso de um hmo
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
TR201820102T4 (tr) Fabri hastalığı gen tedavisi.
BR112016029906A2 (pt) compostos excipientes redutores de viscosidade para formulações proteicas
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
BR112016015187A2 (pt) proteína de fusão para inibição da angiogênese ou do crescimento e uso da mesma
BR112013026114A2 (pt) composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas
BR112017011542A2 (pt) produção de ácido oleico em levedura
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
BR112017023391A2 (pt) ?composição, método para preparar uma composição e métodos para melhorar a hidratação da pele?
BR112016016342A2 (pt) Polipeptídeo variante que tem atividade de lactase, sequência de ácido nucleico, construto de ácido nucleico, vetor de expressão recombinante, método para produzir uma lactase, método para produzir uma variante de polipeptídeo de lactase, composição, uso de um polipeptídeo variante, processo para a produção de um produto lácteo e produto lácteo
BR112017008184A2 (pt) composições e linhagem
BR112019008810A2 (pt) micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer
BR112017012588A2 (pt) compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta)
BR112017027048A2 (pt) processo para extração de pectina e uso da pectina
BR112012033714A2 (pt) polipeptídeo com atividade de acetil xilano esterase e seus usos.
BR112019000201A2 (pt) compostos e seu uso na redução dos níveis de ácido úrico
BR112016015678A2 (pt) Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso
BR112016023688A2 (pt) célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada
BR112017018209A2 (pt) produtos terapêuticos de polipeptídeo e usos dos mesmos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]